Back to results
CompletedPhase 2

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00479557

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Groupe Hospitalier Pitie-Salpetriere

Paris, Cedex 13 (mri), France

+23 additional locations

View on ClinicalTrials.gov
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease — TrialFind